NO950909L - Nitrogensubstituert acridin og inhibitorer for cytochrome P450 og metoder for anvendelse - Google Patents
Nitrogensubstituert acridin og inhibitorer for cytochrome P450 og metoder for anvendelseInfo
- Publication number
- NO950909L NO950909L NO950909A NO950909A NO950909L NO 950909 L NO950909 L NO 950909L NO 950909 A NO950909 A NO 950909A NO 950909 A NO950909 A NO 950909A NO 950909 L NO950909 L NO 950909L
- Authority
- NO
- Norway
- Prior art keywords
- cytochrome
- inhibitors
- nitrogen
- methods
- substituted acridine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Lubricants (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/943,323 US5422350A (en) | 1992-09-10 | 1992-09-10 | Nitrogen substituted acridine and cytochrome P450 inhibitors and methods of use |
US08/100,917 US5466696A (en) | 1992-09-10 | 1993-08-09 | Tacrine and cytochrome P450 oxidase inhibitors and methods of use |
PCT/US1993/008459 WO1994005296A2 (en) | 1992-09-10 | 1993-09-08 | Use of cytochrome p450 inhibitors for inhibiting the metabolism of nitrogen substituted acridine |
Publications (3)
Publication Number | Publication Date |
---|---|
NO950909L true NO950909L (no) | 1995-03-09 |
NO950909D0 NO950909D0 (no) | 1995-03-09 |
NO307955B1 NO307955B1 (no) | 2000-06-26 |
Family
ID=26797688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO950909A NO307955B1 (no) | 1992-09-10 | 1995-03-09 | Blandinger omfattende nitrogensubstituert acridin |
Country Status (18)
Country | Link |
---|---|
US (1) | US5466696A (no) |
EP (1) | EP0659082B1 (no) |
JP (1) | JPH08501105A (no) |
KR (1) | KR950703339A (no) |
AT (1) | ATE212845T1 (no) |
AU (1) | AU669586B2 (no) |
CA (1) | CA2141425A1 (no) |
CZ (1) | CZ48095A3 (no) |
DE (1) | DE69331546T2 (no) |
DK (1) | DK0659082T3 (no) |
ES (1) | ES2171419T3 (no) |
FI (1) | FI951024A0 (no) |
HU (1) | HU217845B (no) |
NO (1) | NO307955B1 (no) |
NZ (1) | NZ256940A (no) |
PT (1) | PT659082E (no) |
SK (1) | SK26495A3 (no) |
WO (1) | WO1994005296A2 (no) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5567592A (en) * | 1994-02-02 | 1996-10-22 | Regents Of The University Of California | Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal |
JPH11507356A (ja) * | 1995-06-07 | 1999-06-29 | アブマックス,インコーポレイティド | 経口薬理化合物の生物有用性を高めるためのエッセンシャルオイルの利用 |
US5716928A (en) * | 1995-06-07 | 1998-02-10 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
US5665386A (en) * | 1995-06-07 | 1997-09-09 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
US6218383B1 (en) * | 1998-08-07 | 2001-04-17 | Targacept, Inc. | Pharmaceutical compositions for the prevention and treatment of central nervous system disorders |
AU779900B2 (en) * | 1999-07-22 | 2005-02-17 | Organogenesis Inc. | In vivo induction for enhanced function of isolated hepatocytes |
US6855542B2 (en) * | 2001-12-21 | 2005-02-15 | Organogenesis Inc. | Chamber with adjustable volume for cell culture and organ assist |
AU2003270446A1 (en) * | 2002-09-25 | 2004-04-19 | The Board Of Trustees Of The University Of Illinois | Method and composition for treating alzheimer's disease and dementias of vascular origin |
US7583551B2 (en) | 2004-03-10 | 2009-09-01 | Micron Technology, Inc. | Power management control and controlling memory refresh operations |
DE102005044815A1 (de) * | 2005-09-20 | 2007-03-22 | Sanofi-Aventis Deutschland Gmbh | Verwendung von Inhibitoren des Na+/H+ Austauschers, Subtyp 5 (NHE5) zur Gedächtnisverbesserung |
WO2008153722A1 (en) * | 2007-05-22 | 2008-12-18 | The Board Of Regents Of The University Of Texas System | Post-translational regulation of catalytic activities of cytochrome p450 46a1 and uses thereof |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2233970A (en) * | 1941-03-04 | Quinoline compound and process of | ||
DE1643240A1 (de) * | 1966-09-16 | 1971-06-24 | Boehringer Sohn Ingelheim | Verfahren zur Herstellung neuer racemischer oder optisch aktiver 1-Phenoxy-2-aminoalkane |
GB1338169A (en) * | 1971-03-09 | 1973-11-21 | Smith Kline French Lab | Ureas thioureas and guanidines |
SU429813A1 (ru) * | 1971-08-20 | 1974-05-30 | Способ лечения туберкулеза легких | |
AR223983A1 (es) * | 1978-08-25 | 1981-10-15 | Dainippon Pharmaceutical Co | Un procedimiento para-preparar derivados de acido 6-halogeno-4-oxo-7-(1-piperazinil)-1,8-naftiridin-3-carboxilico |
SU789112A1 (ru) * | 1979-04-12 | 1980-12-23 | Научно-исследовательский институт экспериментальной и клинической медицины | Способ лечени экстрасистолической аритмии у детей |
SU827081A1 (ru) * | 1979-06-05 | 1981-05-07 | Донецкий Медицинский Институт Им.M.Горького | Способ лечени вазомоторных головныхбОлЕй |
GB2091249A (en) * | 1980-12-23 | 1982-07-28 | Fordonal Sa | Xanthine derivatives |
SU1049065A1 (ru) * | 1981-01-09 | 1983-10-23 | Andronova Liliya Z | Способ лечени заикани |
JPS57134482A (en) * | 1981-02-13 | 1982-08-19 | Dainippon Pharmaceut Co Ltd | 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8- naphthyridine-3-carboxylic acid-3/2 hydrate and its preparation |
SU1156700A1 (ru) * | 1982-01-19 | 1985-05-23 | Научно-Исследовательский Институт Экспериментальной Медицины Амн Ссср | Способ лечени неврозов |
SU1210789A1 (ru) * | 1983-07-21 | 1986-02-15 | Военно-Медицинская Ордена Ленина Краснознаменная Академия Им.С.М.Кирова | Способ диагностики функционального нарушени желудочной секреции |
SU1196002A1 (ru) * | 1984-06-28 | 1985-12-07 | Запорожский государственный институт усовершенствования врачей им.М.Горького | Способ лечени хронического сальпингоофорита |
US4754050A (en) * | 1984-10-25 | 1988-06-28 | Hoechst-Roussel Pharmaceuticals, Inc. | 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds |
EP0179383B1 (en) * | 1984-10-25 | 1991-05-29 | Hoechst-Roussel Pharmaceuticals Incorporated | 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds, a process for their preparation and their use as medicaments |
US4695573A (en) * | 1984-10-25 | 1987-09-22 | Hoechst-Roussel Pharmaceuticals Inc. | 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds |
US4835275A (en) * | 1984-10-25 | 1989-05-30 | Hoechst-Roussel Pharmaceuticals, Inc. | Method of preparing 9-amino-1,2,3,4,-tetrahydroacridin-1-ones and related compounds |
US4631286A (en) * | 1984-10-25 | 1986-12-23 | Hoechst-Roussel Pharmaceuticals Inc. | 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds |
SU1537252A1 (ru) * | 1985-03-28 | 1990-01-23 | Научно-Исследовательский Институт Экспериментальной Медицины Амн Ссср | Способ лечени парестезий полости рта |
SU1416125A1 (ru) * | 1986-02-21 | 1988-08-15 | Одесский Научно-Исследовательский Институт Курортологии | Способ лечени заболеваний суставов |
SU1389050A1 (ru) * | 1986-07-28 | 1990-08-30 | Niiex Meditsiny An Sssr | Cпocoб лeчehия aлkoгoлизma |
US4816456A (en) * | 1986-10-01 | 1989-03-28 | Summers William K | Administration of monoamine acridines in cholinergic neuronal deficit states |
MX13270A (es) * | 1987-10-05 | 1993-06-01 | Pfizer | Procedimiento para la preparacion de derivados de 4-aminopiridina |
US5019395A (en) * | 1988-03-08 | 1991-05-28 | Warner-Lambert Company | Compositions with enhanced penetration |
NZ231376A (en) * | 1988-11-16 | 1992-05-26 | Hoechst Roussel Pharma | Hydroxy-1,2,3,4-tetrahydroaminoacridine derivatives, preparation and pharmaceutical compositions thereof |
GB8827704D0 (en) * | 1988-11-28 | 1988-12-29 | Fujisawa Pharmaceutical Co | New acridine derivatives & processes for their production |
US4999430A (en) * | 1989-07-31 | 1991-03-12 | Warner-Lambert Company | Derivatives of 1,2,3,4-tetrahydro-9-acrisinamine |
-
1993
- 1993-08-09 US US08/100,917 patent/US5466696A/en not_active Expired - Fee Related
- 1993-09-08 DE DE69331546T patent/DE69331546T2/de not_active Expired - Fee Related
- 1993-09-08 KR KR1019950700943A patent/KR950703339A/ko not_active Application Discontinuation
- 1993-09-08 SK SK264-95A patent/SK26495A3/sk unknown
- 1993-09-08 NZ NZ256940A patent/NZ256940A/en unknown
- 1993-09-08 ES ES93923110T patent/ES2171419T3/es not_active Expired - Lifetime
- 1993-09-08 AU AU52905/93A patent/AU669586B2/en not_active Ceased
- 1993-09-08 HU HU9500704A patent/HU217845B/hu not_active IP Right Cessation
- 1993-09-08 CA CA002141425A patent/CA2141425A1/en not_active Abandoned
- 1993-09-08 WO PCT/US1993/008459 patent/WO1994005296A2/en not_active Application Discontinuation
- 1993-09-08 DK DK93923110T patent/DK0659082T3/da active
- 1993-09-08 CZ CZ95480A patent/CZ48095A3/cs unknown
- 1993-09-08 EP EP93923110A patent/EP0659082B1/en not_active Expired - Lifetime
- 1993-09-08 AT AT93923110T patent/ATE212845T1/de not_active IP Right Cessation
- 1993-09-08 PT PT93923110T patent/PT659082E/pt unknown
- 1993-09-08 JP JP6507526A patent/JPH08501105A/ja not_active Ceased
-
1995
- 1995-03-06 FI FI951024A patent/FI951024A0/fi unknown
- 1995-03-09 NO NO950909A patent/NO307955B1/no unknown
Also Published As
Publication number | Publication date |
---|---|
PT659082E (pt) | 2002-07-31 |
WO1994005296A2 (en) | 1994-03-17 |
ES2171419T3 (es) | 2002-09-16 |
SK26495A3 (en) | 1996-05-08 |
DK0659082T3 (da) | 2002-06-17 |
US5466696A (en) | 1995-11-14 |
FI951024A (fi) | 1995-03-06 |
AU5290593A (en) | 1994-03-29 |
HUT70979A (en) | 1995-11-28 |
NO950909D0 (no) | 1995-03-09 |
WO1994005296A3 (en) | 1994-04-28 |
EP0659082B1 (en) | 2002-02-06 |
CZ48095A3 (en) | 1995-12-13 |
FI951024A0 (fi) | 1995-03-06 |
HU9500704D0 (en) | 1995-04-28 |
EP0659082A1 (en) | 1995-06-28 |
HU217845B (hu) | 2000-04-28 |
AU669586B2 (en) | 1996-06-13 |
KR950703339A (ko) | 1995-09-20 |
JPH08501105A (ja) | 1996-02-06 |
NZ256940A (en) | 1996-03-26 |
DE69331546T2 (de) | 2002-10-31 |
NO307955B1 (no) | 2000-06-26 |
DE69331546D1 (de) | 2002-03-21 |
CA2141425A1 (en) | 1994-03-17 |
ATE212845T1 (de) | 2002-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE93138T1 (de) | Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie. | |
DE69924641D1 (de) | Behandlung von asthma anhand von mek-inhibitoren | |
DE60112055D1 (de) | Inhibitoren von gamma-secretase | |
ATE168268T1 (de) | Behandlung von menschlichen retrovirus- infektionen mit 2',3'-dideoxyinosin | |
ATE209483T1 (de) | Behandlung von multipler sklerose | |
DE60124684D1 (de) | Sulfonamido-substituierte verbrückte bicycloalkylderivative | |
DE69532961D1 (de) | Verwendung von porphyrine in der behandlung von multiple sklerose | |
NO993847L (no) | FremgangsmÕter og preparater for behandling av allergisk astma og andre sykdommer ved anvendelse av deskarboetoksyloratadin | |
DK0858330T3 (da) | Præparater indeholdende derivater af hydroperoxyeicosatetraensyre og fremgangsmåder til anvendelse ved behandling af sygdom | |
NO950909D0 (no) | Nitrogensubstituert acridin og inhibitorer for cytochrome P450 og metoder for anvendelse | |
FI913142A (fi) | Migraenfoerhindrande alkoxipyrimidinderivat. | |
DE59511017D1 (de) | [a]-ANNELIERTE PYRROLDERIVATE UND DEREN ANWENDUNG IN DER PHARMAZIE | |
DE3686582D1 (de) | Behandlung einer krankheit vom aids-typ. | |
DK0739212T3 (da) | Anvendelse af interleukin-12 til forebyggelse af transplantat-vs.-værtssygdom | |
NO943874L (no) | Behandling av resistant neoplasma | |
DE69834724D1 (de) | Behandlung von Darm- oder Blasenentzündungen | |
FR2731907B1 (fr) | Composition dermatologique et/ou cosmetique depigmentante et utilisation dans une methode cosmetique | |
NO894222L (no) | Fremgangsmaater for behandling og profylakse av pneumocytis carinii pneumoni og andre sykdommer og forbindelser og formuleringer for anvendelse i nevnte metoder. | |
ATE190843T1 (de) | Zubereitungen zur behandlung von impotenz, die ein alpha-1 inhibitor und ein alpha-2 inhibitor enthalten | |
DE59107536D1 (de) | Arzneimittel zur behandlung von hyperlipidämie und/oder atherosklerose | |
ES2120251T3 (es) | 3-alcoxicarbonil-tiadiazinonas cardioactivas. | |
ATE229343T1 (de) | Kombination von temozolomide und alpha-interferon zur behandlung von fortgeschrittenem krebs | |
NO972435L (no) | 2-(2,3,5,6-tetrafluor-4-pyridyl)-1,2,5-tradiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav | |
ATE335494T1 (de) | Verwendung von n-glycolneuraminsäure und deren derivaten zur herstellung eines medikaments zur behandlung von hiv-infektionen | |
KR940003550A (ko) | 노인성 치매 예방 및 치료방법 |